نتائج البحث - "Real-life clinical practice"

المساهمون: Institut Gustave Roussy (IGR), Oncostat (U1018 (Équipe 2)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique Gustave Roussy, Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Léon Bérard Lyon, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Dermatologie AP-HP Hôpital Saint-Louis, Hopital Saint-Louis AP-HP (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Université de Montpellier (UM), Centre Hospitalier Universitaire de Bordeaux (CHU de Bordeaux), Centre Hospitalier Universitaire CHU Grenoble (CHUGA), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Ambroise Paré AP-HP, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), AP-HP - Hôpital Bichat - Claude Bernard Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Amiens-Picardie, Hôpital Haut-Lévêque CHU Bordeaux, CHU Bordeaux, Hôpital Avicenne AP-HP, CRLCC Eugène Marquis (CRLCC), UNICANCER, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital de la Timone CHU - APHM (TIMONE), Service de Dermatologie et Allergologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Universitaire Carémeau Nîmes (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Groupe de Recherche et d'Accueil en Droit et Economie de la Santé (GRADES), Université Paris-Saclay, This research was funded by the French Institute National of Cancer (DOC 16-009).

المصدر: ISSN: 1718-7729 ; Current Oncology ; https://hal.science/hal-04049403Test ; Current Oncology, 2022, 29 (12), pp.9255-9270. ⟨10.3390/curroncol29120725⟩.

مصطلحات موضوعية: Targeted therapy, Advanced melanoma, Cost-effectiveness analysis, Immunotherapy, Real-life clinical practice, MESH: Cost-Benefit Analysis, MESH: Cost-Effectiveness Analysis, MESH: France, MESH: Humans, MESH: Melanoma, MESH: Prospective Studies, MESH: Proto-Oncogene Proteins B-raf, JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I18 - Government Policy • Regulation • Public Health, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SHS.ECO]Humanities and Social Sciences/Economics and Finance

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36547139; hal-04049403; https://hal.science/hal-04049403Test; https://hal.science/hal-04049403/documentTest; https://hal.science/hal-04049403/file/curroncol-29-00725.pdfTest; PUBMED: 36547139; PUBMEDCENTRAL: PMC9777106; WOS: 000900583900001

الإتاحة: https://doi.org/10.3390/curroncol29120725Test
https://hal.science/hal-04049403Test
https://hal.science/hal-04049403/documentTest
https://hal.science/hal-04049403/file/curroncol-29-00725.pdfTest

View record in BASE

6

دورية أكاديمية

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

المؤلفون: Vianelli, Nicola, Auteri, Giuseppe, Buccisano, Francesco, Carrai, Valentina, Baldacci, Erminia, Clissa, Cristina, Bartoletti, Daniela, Giuffrida, Gaetano, Magro, Domenico, Rivolti, Elena, Esposito, Daniela, Podda, Gian Marco, Palandri, Francesca

المساهمون: N. Vianelli, G. Auteri, F. Buccisano, V. Carrai, E. Baldacci, C. Clissa, D. Bartoletti, G. Giuffrida, D. Magro, E. Rivolti, D. Esposito, G.M. Podda, F. Palandri

مصطلحات موضوعية: Combination therapy, Immune thrombocytopenia (ITP), Real-life clinical practice, Refractory ITP, Rituximab, Thrombopoietin receptor agonists (TPO-RA), Human, Receptors, Fc, Thrombopoietin, Recombinant Fusion Protein, Splenectomy, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia, Settore MED/09 - Medicina Interna

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35201417; info:eu-repo/semantics/altIdentifier/wos/WOS:000761265100001; volume:101; issue:5; firstpage:963; lastpage:978; numberofpages:16; journal:ANNALS OF HEMATOLOGY; https://hdl.handle.net/2434/936153Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85125140991

الإتاحة: https://doi.org/10.1007/s00277-022-04786-yTest
https://hdl.handle.net/2434/936153Test

View record in BASE

7

دورية أكاديمية

Preoperative Intensified Chemoradiation with Intensity-Modulated Radiotherapy and Simultaneous Integrated Boost Combined with Capecitabine in Locally Advanced Rectal Cancer: Long-Term Outcomes of a Real-Life Multicenter Study

المؤلفون: Lupattelli M., Palazzari E., Polesel J., Chiloiro G., Angelicone I., Panni V., Caravatta L., Di Biase S., Macchia G., Niespolo R. M., Franco P., Epifani V., Meldolesi E., de Giacomo F., Lucarelli M., Montesi G., Mantello G., Innocente R., Osti M. F., Gambacorta M. A., Aristei C., De Paoli A.

المساهمون: Lupattelli, M., Palazzari, E., Polesel, J., Chiloiro, G., Angelicone, I., Panni, V., Caravatta, L., Di Biase, S., Macchia, G., Niespolo, R. M., Franco, P., Epifani, V., Meldolesi, E., de Giacomo, F., Lucarelli, M., Montesi, G., Mantello, G., Innocente, R., Osti, M. F., Gambacorta, M. A., Aristei, C., De Paoli, A.

مصطلحات موضوعية: preoperative chemoradiotherapy (CRT), intensity modulated RT (IMRT), long-term results, radiotherapy dose, real-life clinical practice, rectal cancer, simultaneous integrated boost (SIB)

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38067405; info:eu-repo/semantics/altIdentifier/wos/WOS:001116124200001; volume:15; issue:23; numberofpages:18; journal:CANCERS; https://hdl.handle.net/11391/1566633Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85179373553; https://doi.org/10.3390Test/ cancers15235702

الإتاحة: https://doi.org/10.3390/cancers15235702Test
https://hdl.handle.net/11391/1566633Test

View record in BASE

8

دورية أكاديمية

Nivolumab in real-life clinical practice ; Ниволумаб в реальной клиническом практике

المؤلفون: M. Lyadova A., O. Pardabekova A., R. Shakirov R., V. Lyadov K., M. Fedyanin Yu., М. Лядова А., О. Пардабекова А., Р. Шакиров Р., В. Лядов К., М. Федянин Ю.

المصدر: Research and Practical Medicine Journal; Том 6, № 4 (2019); 84-91 ; Research'n Practical Medicine Journal; Том 6, № 4 (2019); 84-91 ; 2410-1893 ; 2409-2231 ; 10.17709/2409-2231-2019-6-4

مصطلحات موضوعية: immune therapy, nivolumab, melanoma, non-small cell lung cancer, metastatic colorectal cancer, real-life clinical practice, иммунотерапия, ниволумаб, меланома, немелкоклеточный рак легкого, метастатический коло-ректальный рак, реальная клиническая практика

وصف الملف: application/pdf

العلاقة: https://www.rpmj.ru/rpmj/article/view/463/332Test; Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med. 2011 Nov 30; 3(m):U1ra120. DOI:10.1126/scitranslmed.3003130; Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014 April 1; 32(10):1020-1030. DOI:10.1200/JCO.2013.53.0105; Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Jun 22; 376 (25):2415—2426. DOI:10.1056/NEJMoa1613493; Smith KM, Desai J. Nivolumab for the treatment of colorectal cancer. Journal Expert Review of Anticancer Therapy. 2018 Jul; 18(7):611—618. DOI:10.1080/14737140.2018.1480942; Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017 Apr; 6(2):196—211. DOI:10.21037/tlcr.2017.03.01; Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, et al. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. Clin Lung Cancer. 2019 May 19; 20(3):178-185.e2. DOI:10.1016/j.cllc.2019.02.001; Topalian SL, Hodi FS, Brahmer JR, Geffinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med. 2012 Jun 28; 366 (26):2443—2454. DOI:10.1056/NEJMoa1200690; Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in Previously Untreated Melanoma without BRAF. N Engl J Med. 2015 Jan 22; 372(4):320-330. DOI:10.1056/NEJMoa1412082; Geffinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Riz- vi NA, et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-2012. DOI:10.1200/JC0.2014.58.3708; Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21; 372 (21):2006—2017. DOI:10.1056/NEJMoa1414428; Rounds A, Kolesar J. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer. Am J Health Syst Pharm. 2015 Nov 1;72(21):1851-1855. DOI:10.2146/ajhp150235; Sundar R, Cho BC, Brahmer JR, Soo RA. Nivolumab in NS-CLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar; 7(2):85-96. DOI:10.1177/1758834014567470; Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012 Sep-Oct; 62(5):309-335. DOI:10.3322/caac.20132; Ledford H. Cancer treatment: The killer within. Nature. 2014 Apr 3; 508 (7494):24-26. DOI:10.1038/508024a; Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011 Dec 20; 29(36):4828-4836. DOI:10.1200/JCO.2011.38.0899; Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28; 366(26):2455- 2465. DOI:10.1056/NEJMoa1200694; Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2018; 36(4):383-390. DOI:10.1200/JCO.2016.71.8023; Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, et al. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. Eur J Cancer. 2018; 102:23-30. DOI:10.1016/j.ejca.2018.05.005; Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182-1191. DOI:10.1016/S1470-2045(17)30422-9; https://www.rpmj.ru/rpmj/article/view/463Test

الإتاحة: https://doi.org/10.17709/2409-2231-2019-6-4-8Test
https://doi.org/10.17709/2409-2231-2019-6-4Test
https://doi.org/10.1126/scitranslmed.3003130Test
https://doi.org/10.1200/JCO.2013.53.0105Test
https://doi.org/10.1056/NEJMoa1613493Test
https://doi.org/10.1080/14737140.2018.1480942Test
https://doi.org/10.21037/tlcr.2017.03.01Test
https://doi.org/10.1016/j.cllc.2019.02.001Test
https://doi.org/10.1056/NEJMoa1200690Test
https://doi.org/10.1056/NEJMoa1412082Test